Compare RRC & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RRC | LNTH |
|---|---|---|
| Founded | 1976 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 6.6B |
| IPO Year | 1996 | 2014 |
| Metric | RRC | LNTH |
|---|---|---|
| Price | $41.24 | $100.39 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 18 | 6 |
| Target Price | $43.67 | ★ $87.00 |
| AVG Volume (30 Days) | ★ 1.9M | 1.1M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | ★ 151.38 | N/A |
| EPS | 2.27 | ★ 2.91 |
| Revenue | ★ $3,115,515,000.00 | $343,374,000.00 |
| Revenue This Year | $15.60 | N/A |
| Revenue Next Year | $9.73 | $14.19 |
| P/E Ratio | ★ $18.39 | $34.60 |
| Revenue Growth | ★ 28.90 | 3.62 |
| 52 Week Low | $32.68 | $49.67 |
| 52 Week High | $48.31 | $111.86 |
| Indicator | RRC | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 59.97 | 45.34 |
| Support Level | $40.16 | $100.51 |
| Resistance Level | $43.77 | $101.43 |
| Average True Range (ATR) | 1.01 | 0.52 |
| MACD | -0.04 | 0.10 |
| Stochastic Oscillator | 62.37 | 38.70 |
Range Resources is an exploration and production firm whose operations represent a pure play in the Marcellus shale, located in the Appalachian region of Southwest Pennsylvania. The company went public as Lomak Petroleum in 1980 and later reorganized as Range Resources in 1998. After an expensive 10-year venture with a multi-basin strategy, Range Resources found its identity as an Appalachian natural gas producer, offloading its Permian assets in 2013. Range quickly became a leading US gas producer after its merger with Memorial Resource Development in 2016. Following the merger, Range saw its operational unit costs rise to an uncompetitive level and subsequently sold the assets in 2020 to return to its roots as an Appalachian producer.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.